Capmatinib in patients with high-level MET-amplified advanced non–small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.
暂无分享,去创建一个
H. Groen | T. Overbeck | E. Smit | R. Heist | D. Tan | J. Wolf | Ji-Youn Han | M. Giovannini | M. Hochmair | E. Garon | D. Power | K. Ohashi | F. Marinis | N. Nwana | M. Waldron-Lynch | S. L. Mouhaer | Sylvie Le Mouhaer